146 related articles for article (PubMed ID: 33380679)
1. Lutetium therapy-induced carcinoid crisis: A case report and review of literature.
Yadav SK; Jha CK; Patil S; Datta D; Mishra A; Pradhan PK
J Cancer Res Ther; 2020 Dec; 16(Supplement):S206-S208. PubMed ID: 33380679
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid crisis after biopsy of a bronchial carcinoid.
Karmy-Jones R; Vallières E
Ann Thorac Surg; 1993 Dec; 56(6):1403-5. PubMed ID: 8267450
[TBL] [Abstract][Full Text] [Related]
3. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
[TBL] [Abstract][Full Text] [Related]
4. Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions.
Tapia Rico G; Li M; Pavlakis N; Cehic G; Price TJ
Cancer Treat Rev; 2018 May; 66():1-6. PubMed ID: 29602040
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
6. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
van Essen M; Krenning EP; Bakker WH; de Herder WW; van Aken MO; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1219-27. PubMed ID: 17260141
[TBL] [Abstract][Full Text] [Related]
8. Metastatic renal carcinoid: case report and review of the literature.
Tal R; Lask DM; Livne PM
Urology; 2003 Apr; 61(4):838. PubMed ID: 12670585
[TBL] [Abstract][Full Text] [Related]
9. Repurposed Effect of
Elajami MK; Burton LP; Bahmad HF; Chaaya G; Schwartz M
Curr Oncol; 2022 Oct; 29(10):7552-7557. PubMed ID: 36290871
[TBL] [Abstract][Full Text] [Related]
10. Coincidental visualization of an atypical bronchial carcinoid on Tc-99m-sestamibi scan in Kallmann's syndrome.
Yapar Z; Kibar M; Sükan A; Paydaş S; Zeren H; Inal M
Ann Nucl Med; 2002 Feb; 16(1):61-5. PubMed ID: 11922210
[TBL] [Abstract][Full Text] [Related]
11. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
12. Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report.
Dhanani J; Pattison DA; Burge M; Williams J; Riedel B; Hicks RJ; Reade MC
J Crit Care; 2020 Dec; 60():319-322. PubMed ID: 32928590
[TBL] [Abstract][Full Text] [Related]
13. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
14. Bronchial typical carcinoid tumors.
Morandi U; Casali C; Rossi G
Semin Thorac Cardiovasc Surg; 2006; 18(3):191-8. PubMed ID: 17185178
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
16. Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.
Del Olmo-García MI; Muros MA; López-de-la-Torre M; Agudelo M; Bello P; Soriano JM; Merino-Torres JF
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664679
[TBL] [Abstract][Full Text] [Related]
17.
Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
[TBL] [Abstract][Full Text] [Related]
18. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
